Nalaganje...
Clinical pharmacology of alemtuzumab, an anti‐CD52 immunomodulator, in multiple sclerosis
Alemtuzumab, a humanized anti‐CD52 monoclonal antibody, is approved for treatment of relapsing multiple sclerosis (MS). In the Phase II/III trials, patients received 12 or 24 mg/day of alemtuzumab in two treatment courses (5 days for course 1 and 3 days for course 2), 12 months apart. Serum concentr...
Shranjeno v:
| izdano v: | Clin Exp Immunol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6231011/ https://ncbi.nlm.nih.gov/pubmed/30144037 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13208 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|